GlassScriptPhysician profile
Jerry P Wilson
NPI 1144206962
$2,844.57
in general payments reported to CMS, 2019-2025
22 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $227 · 2021: $42.57 · 2022: $51.68 · 2023: $518 · 2024: $739 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.63 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.89 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $600.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $431.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $269.23 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $116.55 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $105.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $100.87 | 2023-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.47 | 2020-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.23 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $67.12 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $61.92 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $61.41 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $38.08 | 2020 | |
| Merck Sharp & Dohme LLC | $37.99 | 2023-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $25.27 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.12 | 2024-2025 | Voquezna |
| Seqirus USA INC | $18.71 | 2024 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2023 | |
| Eisai INC. | $15.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2020 | |
| Allergan, INC. | $13.65 | 2019 | |
| Sanofi Pasteur INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.